Our study has suggested that HIF-α, especially HIF-2α, is a promising therapeutic target for ferroptosis induction in chemoresistant GBM and exposed the potential of roxadustat as a new treatment option for patients with refractory GBM. Here, EPAS1 is linked to glioblastoma.